IUGNF - Imugene says Azer-cel could be best-in-class Allogeneic CAR T

(NewsDirect)

Imugene Ltd(ASX:IMU) CEO Leslie Chong speaks with Proactive soon after announcingthe company has passed a major milestone for its Azer-cel therapytreatment with the dosing of the first patient for its Phase 1bAllogeneic CAR T Clinical Trial. It follows a Phase 1a trial thatincluded 84 patients across leading US healthcare centres and offeredstrong safety and efficacy signals according to IMU. The second partof this Phase 1 trial involves the study of Azer-cel in an ongoing,multi-centre clinical trial in patients with non-Hodgkin’s lymphomablood cancer, and serves as a precursor to Phase 2 registrational(subject to FDA approval) in 2024.

“It is a great credit to our team that the Phase1b study has been initiated and the first patient dosed, in underthree months since acquiring the technology,” Chong said.

ContactDetails

Proactive Investors

JonathanJackson

+61 413 713 744

Jonathan@proactiveinvestors.com

Copyright (c) 2023 TheNewswire - All rights reserved.